... BERKELEY Calif. Feb. 6 /- Nile Therapeuti... We are very excited that dosing has begun in this important dose-esc...The primary objectives of the study are to assess the safety andtoler...About CD-NP ...

BERKELEY, Calif., Feb. 6 /PRNewswire-FirstCall/ -- Nile Therapeutics,
Inc. (OTC Bulletin Board: NILT), today announced that the first heart
failure patient has been dosed in its Phase Ib, multi-center, open-label,
ascending dose clinical study of the company's lead product candidate,
CD-NP, a novel chimeric natriuretic peptide, in development for the
treatment of acute decompensated heart failure.

"We are very excited that dosing has begun in this important dose-
escalation study of CD-NP in heart failure patients," said Peter Strumph,
Chief Executive Officer of Nile. "CD-NP has the potential to fill a large
unmet medical need in the treatment of heart failure. This trial provides
us our first opportunity to assess the drug's activity in heart failure
patients, and to further build on our understanding of the molecule's
mechanism of action."

The primary objectives of the study are to assess the safety and
tolerability of intravenous infusions of CD-NP in patients with heart
failure. Safety assessments include measurement of blood pressure, heart
rate, serum potassium and kidney function as calculated by glomerular
filtration rate (GFR). Clinical assessments include urine flow rate, sodium
excretion rate and plasma cGMP, a secondary messenger of the target
receptor. The trial is expected to enroll up to approximately 35 patients.
Results from the trial are expected to be available in 2008.

About CD-NP

CD-NP is a rationally-designed synthetic peptide that combines selected
components of naturally occurring natriuretic peptides to create a novel,
NPR- B agonist which has a favorable pharmacological profile with potent
renal enhancement and cardiac unloading properties, but minimal hypotensive
effects. Data from Nile's recently completed Phase Ia study in 22 healthy
volunteers was consistent with several pre-clinical findings, including
that CD-NP was associated with increased levels of plasma cGMP, a secondary
messenger of the target receptor, preserved renal function, increased
natriuresis and diuresis with no effect on mean arterial pressure.

About Heart Failure

Heart failure is a chronic condition in which the heart cannot
effectively pump enough blood to the body's other organs. Heart failure is
the fastest- growing clinical cardiac disease in the United States,
affecting 5 million Americans. In the U.S., more than $30 billion is spent
each year to treat heart failure. Approximately 1 million patients in the
U.S. each year are hospitalized with acute decompensated heart failure
(ADHF). These ADHF patients face high rates of morbidity and mortality
following hospital discharge, with 6-month hospital re-admission and
12-month mortality rates of 50% and 33%, respectively.(*)

About Nile Therapeutics

Nile Therapeutics, Inc. is a clinical-stage biopharmaceutical company
that develops innovative products for the treatment of cardiovascular
disease and other areas of unmet medical need. Nile is initially focusing
its efforts on developing its lead compound, CD-NP, a novel chimeric
peptide in Phase I studies for the treatment of acute decompensated heart
failure, and 2NTX-99, a small molecule, pre-clinical, anti-atherothrombotic
agent with nitric oxide donating properties. A key component of the
Company's strategy is to acquire the global rights to additional compounds
to expand its portfolio. More information on Nile can be found at
http://www.nilethera.com.

This press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995 that
involve substantial risks and uncertainties. All statements, other than
statements of historical facts, included in this press release regarding
our strategy, future operations, outlook, milestones, the success of Nile's
product development, future financial position, future financial results,
plans and objectives of management are forward-looking statements. We may
not actually achieve these plans, intentions or expectations and Nile
cautions investors not to place undue reliance on our forward-looking
statements. Actual results or events could differ materially from the
plans, intentions and expectations disclosed in the forward-looking
statements we make. Various important factors that could cause actual
results or events to differ materially from the forward-looking statements
that we make are described in greater detail in the reports we file with
Securities and Exchange Commission, including the "Risk Factors" section of
our Prospectus filed pursuant to Rule 424(b)(3) of the Securities Act of
1933, as amended, with the Securities and Exchange Commission on November
15, 2007. Nile is providing this information as of the date of this press
release and does not undertake any obligation to update any forward-looking
statements as a result of new information, future events or otherwise.

(Date:10/12/2017)... ... October 12, 2017 , ... ... healthcare compliance program management, will showcase a range of technology and learning solutions ... Living (NCAL) Convention and Expo to be held October 14–18, 2017 at the ...

(Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ), one ... an innovative new design of the shoulder pad. The shoulder pad provides optimal ... controlling your pain while using cold therapy. By utilizing ice and water that is ...

(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... been named one of Michigan’s 2017 Best and Brightest in Wellness® by Best ... in Wellness® awards program on Friday, Oct. 20 from 7:30 a.m. to 2 ...

(Date:10/12/2017)... ... October 12, 2017 , ... Farm Forward ... and other leading institutions in announcing the launch of the Leadership Circle ... way animals are raised for food. , Founding members of the Leadership Circle ...

(Date:10/2/2017)... Lilly and Company (NYSE: LLY ) will ... 2017 on Tuesday, October 24, 2017. Lilly will also ... investment community and media to further detail the company,s ... at 9 a.m. Eastern time. Investors, media and the ... conference call through a link that will be posted ...